Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Chinese Image Providers Shut Down for ‘Illegal’ Work With Foreign News
Shanghai Court Freezes Assets of Wanda Group Founder’s Son Wang Sicong
Xiaomi Budget Brand Redmi Releases Cheaper Than Expected 5G Smartphone
LATEST
Hillhouse-Backed Genor Plans $200 Million Hong Kong IPO
GitHub Looks to Open Subsidiary in China
5G Handsets Grow As Proportion Of China’s Sluggish Smartphone Market
China Executes Man Who Killed 3 Fearing Wife’s Forced Abortion Under One-Child Policy
Agriculture Insurance Companies Take A Hit From African Swine Fever
Tencent-Backed News App Denies Explosive Fraud Allegations From U.S. Due-Diligence Firm
Defying Sentiment, WeWork’s China Rival Files for New York IPO
Electric Car Maker Nio Cuts 141 Jobs at North American Headquarters
Huawei Wins Telefonica Deal to Help Build German 5G Network
China Unveils First 3D Images From Newest Earth Observation Satellite
Tesla to Raise Prices in China Again, Sources Say
Didi Considered Safest Ride-Hailing Platform Despite Murders, Survey Shows
Risks and Benefits of China’s Private Sector Bailout
Xiaomi Budget Brand Redmi Releases Cheaper Than Expected 5G Smartphone
Major Chinese Freight Line Sees Shipments Fall 8% Amid Slumping Coal Demand
Sales of Chinese-Made Excavators Slow Amid Cooling Infrastructure Investment
BAIC Slump Persists With Bleak November NEV Figures
Shanghai Court Freezes Assets of Wanda Group Founder’s Son Wang Sicong
ByteDance Eyes Another TikTok-Like Success With New Music App
Chinese Cellphone Maker Oppo Expands Smart Hardware Offerings
China Approves Older Novartis MS Drug

By Matthew Walsh / Jul 20, 2019 05:37 AM / Business & Tech

Photo: VCG

Photo: VCG

Novartis International AG won approval in China to sell its multiple sclerosis (MS) drug Gilenya, Reuters reports, deepening the Swiss pharmaceutical giant's business ties to the huge Chinese health care market and promising to shake up the treatment of what has traditionally been a poorly managed disease there.

MS is the most common autoimmune disease affecting the central nervous system. Around 30,000 people in China live with the condition, according to state news agency Xinhua. That compares with nearly 1 million people in the U.S. suffering the disease, according to a study by the National MS Society.

However, low awareness of MS in China means that the actual number of people with the disease may be significantly higher. In May, Chinese doctors urged both health-care professionals and the general public to learn more about the disease, adding that 95% of people knew nothing about MS before they were diagnosed.

MS occurs when the body’s immune system attacks the fatty sheaths around the nerves, disrupting their ability to send messages to one another. As MS progresses, it causes muscle and cognitive problems and can lead to lasting disabilities.

Although there is no one-size-fits-all cure, a number of treatments can significantly slow the progression of MS. China has long been playing catch-up with Western countries in rolling out such treatments, however, and comparatively few are yet available there.

One such drug, teriflunomide — sold under the trademark Aubagio — was approved by the U.S. Food and Drug Administration in 2012 but gained approval in China only last year.

Gilenya sales earned Novartis $825 million during the second quarter, making it the company’s second-largest source of revenue, Reuters said, adding that the drug has been available in the United States for almost a decade but is now being challenged by generic rivals, spurring Novartis’s push into other markets.

Related: In Depth: Why China’s Drug Review Revamp Is Stalling

Contact reporter Matthew Walsh (matthewwalsh@caixin.com)

Share this article
Open WeChat and scan the QR code